Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seres Readies C. Diff Microbiome Drug For Phase III, Seeks Global Partner

This article was originally published in The Pink Sheet Daily

Executive Summary

Microbiome-focused Seres, which named former Merck and J&J infectious disease chief Roger Pomerantz its CEO in June, has produced strong Phase I/IIb trial results with its lead Ecobiotic candidate and plans to move SER-109 into Phase III later this year. The biotech recently got a ruling that will provide patent protection for SER-109 into 2033.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts